Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.